Sign in to fuzzto save your conversations, follow your research and come back anytime.
Metropolis Healthcare
SectorHealthcare
Metropolis Healthcare Limited is an Indian diagnostic services company operating across India and Africa. Founded in 1980 as a pathology partnership, it has evolved into a public company offering a wide range of clinical laboratory tests and profiles. The company operates through a hub and spoke model with 115 clinical laboratories, including a global reference laboratory in Mumbai, regional reference laboratories, satellite laboratories, and express laboratories. Metropolis provides services to both B2B and B2C markets, covering 197 cities in India and has operations in several African countries. The company offers approximately 3,487 clinical laboratory tests and 530 profiles, and has expanded its network through acquisitions and mergers. Metropolis is known for its quality diagnostics and has received awards for customer service and healthcare excellence.
In the news
Metropolis Healthcare shares surge 8% on strong Q1 results, JM Financial calls best-value stock
Morgan Stanley, AMCs Buy ₹118 Cr Metropolis Shares from Promoters
Metropolis Healthcare Q1 profit jumps 26% to ₹57 crore
Precision Oncology Emerges as Next Major Healthcare Wealth Shift
Metropolis Healthcare leads BSE 'A' group losers on June 22
Metropolis Healthcare posts strong Q4 growth, eyes 14-15% CAGR
Metropolis Healthcare Q4 PAT surges 75% to ₹51 cr, stock rallies
eClerx Services Q4 profit jumps 24.45% to ₹189.36 crore
Metropolis Healthcare Q4 profit jumps 132% to ₹51 crore
Q4 results today: Airtel profit drops 34%, TVS Motor up 37%
Metropolis Healthcare Goes Ex-Bonus Today: 3:1 Ratio Issue
Metropolis Healthcare announces first-ever 3:1 bonus issue
Metropolis Healthcare shares rise 3% on strong Q3 growth
The Quarter story
The two most recent quarterly results, compared side-by-side.
Metropolis Healthcare drives strong organic growth and margin expansion, though rising finance costs and slowed lab rollouts warrant attention.
B2C Revenue grew from ₹214 Cr to ₹251 Cr from Q1 to Q4 FY26, driven by sustained retail test uptake.
Finance Cost increased from ₹3.7 Cr to ₹7.0 Cr from Q1 to Q4 FY26, indicating rising borrowing expenses.
EBITDA Margin expanded from 24.7% to 27.2% from Q1 to Q4 FY26, signaling excellent cost control.
Labs added declined from 12 to 2 from Q1 to Q3 FY26, suggesting slowed diagnostic facility rollout.
Centres added surged from 80 to 490 from Q1 to Q4 FY26, highlighting aggressive network expansion.
B2B Revenue stabilized at ₹174 Cr in Q4 FY26 after starting at ₹172 Cr in Q1 FY26, reflecting normalized contract cycles.
TruHealth Revenue climbed from ₹64 Cr to ₹281 Cr from Q1 to Q4 FY26, fueled by corporate wellness deals.
Depreciation rose from ₹30.8 Cr to ₹38.6 Cr from Q1 to Q4 FY26, indicating heavy asset utilization.
Revenue Per Patient rose from ₹1,151 to ₹1,210 from Q1 to Q4 FY26, proving successful upselling.
Service Points dropped from 4,616 to 295 from Q1 FY26 to Q1 FY27, suggesting a reporting methodology change.